Pages that link to "Q37395858"
Jump to navigation
Jump to search
The following pages link to The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. (Q37395858):
Displaying 50 items.
- Management of endocrine disease: Secondary osteoporosis: pathophysiology and management (Q26998249) (← links)
- Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data (Q31026858) (← links)
- Gastrointestinal motility disorders in children (Q33561975) (← links)
- Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm. (Q33725981) (← links)
- Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System (Q33912042) (← links)
- Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature (Q34272136) (← links)
- Calcium revisited: part II calcium supplements and their effects (Q34304470) (← links)
- The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. (Q34562517) (← links)
- PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis (Q35683846) (← links)
- Acid-suppressive medications and risk of fracture: an updated meta-analysis. (Q35986330) (← links)
- The Indications, Applications, and Risks of Proton Pump Inhibitors (Q36091187) (← links)
- Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data (Q36378748) (← links)
- Prevention, detection, and treatment of osteopenia and osteoporosis (Q37099372) (← links)
- Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update. (Q37247769) (← links)
- Calcium revisited: part I. (Q37281080) (← links)
- Effects of Proton Pump Inhibitor Administration and Intake of a Combination of Yogurt and Galactooligosaccharides on Bone and Mineral Metabolism in Rats (Q37373993) (← links)
- Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). (Q37392391) (← links)
- Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials (Q37671220) (← links)
- The role of the gastrointestinal tract in calcium homeostasis and bone remodeling (Q38093799) (← links)
- A biomechanical sorting of clinical risk factors affecting osteoporotic hip fracture (Q38585164) (← links)
- Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors (Q38612952) (← links)
- Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: Implication for the treatment of postmenopausal bone loss. (Q38675617) (← links)
- A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety (Q38724116) (← links)
- Correlation between proton pump inhibitors and risk of pyogenic liver abscess (Q38824710) (← links)
- Acid-Suppressive Therapy and Risk of Infections: Pros and Cons (Q38865456) (← links)
- Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis (Q40010387) (← links)
- Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence (Q40071378) (← links)
- Forearm fractures in Central Norway, 1999-2012: incidence, time trends, and seasonal variation (Q40093395) (← links)
- Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. (Q40475429) (← links)
- Proton pump inhibitors and risk of bone fractures (Q43426137) (← links)
- Rates of non-vertebral osteoporotic fractures in rheumatoid arthritis and postfracture osteoporosis care in a period of evolving clinical practice guidelines (Q45764017) (← links)
- CCN1 sensitizes esophageal cancer cells to TRAIL-mediated apoptosis (Q46722317) (← links)
- Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study. (Q47147817) (← links)
- The natural history of perforated foregut ulcers after repair by omental patching or primary closure (Q50516738) (← links)
- Effects of the Histamine 1 Receptor Antagonist Cetirizine on the Osteoporotic Phenotype in H( ) /K( ) ATPase Beta Subunit KO Mice (Q50931979) (← links)
- Medication use before and after hip fracture: a population-based cohort and case-control study (Q51140318) (← links)
- Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae (Q51578494) (← links)
- Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. (Q52687792) (← links)
- Proton-pump inhibitors and risk of fractures: an update meta-analysis. (Q55059359) (← links)
- Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study (Q57213305) (← links)
- Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors (Q57271829) (← links)
- Quantifying Candidacy for Deprescribing of Proton Pump Inhibitors among Long-Term Care Residents (Q58557250) (← links)
- Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis (Q58780145) (← links)
- Bone: proton-pump inhibitors and fractures (Q84928291) (← links)
- [Pharmacogenic osteoporosis beyond cortisone. Proton pump inhibitors, glitazones and diuretics] (Q87674168) (← links)
- Proton pump inhibitor use and the risk of fractures among an older adult cohort (Q87917789) (← links)
- Discontinuing Long-Term PPI Therapy: Why, With Whom, and How? (Q88108383) (← links)
- Increased Fracture Risk with Furosemide Use in Children with Congenital Heart Disease (Q88649270) (← links)
- Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women (Q88651591) (← links)
- Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies (Q90418889) (← links)